Skip to main content

Advertisement

SpringerLink
Log in

Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this work is to investigate the characteristics of eyes failing to maintain visual acuity (VA) receiving variable dosing ranibizumab for neovascular age-related macular degeneration (nAMD) after three initial loading doses.

Methods

A consecutive series of patients with nAMD, who, after three loading doses of intravitreal ranibizumab (0.5 mg each), were re-treated for fluid seen on optical coherence tomography. After exclusion of eyes with previous treatment, follow-up less than 12 months, or missed visits, 99 patients were included in the analysis. The influence of baseline characteristics, initial VA response, and central retinal thickness (CRT) fluctuations on the VA stability from month 3 to month 24 were analyzed using subgroups and multiple regression analyses.

Results

Mean follow-up duration was 21.3 months (range 12–40 months, 32 patients followed-up for ≥24 months). Secondary loss of VA (loss of five letters or more) after month 3 was seen in 30 patients (mean VA improvement from baseline +5.8 letters at month 3, mean loss from baseline –5.3 letters at month 12 and –9.7 at final visit up to month 24), while 69 patients maintained vision (mean gain +8.9 letters at month 3, +10.4 letters at month 12, and +12.8 letters at final visit up to month 24). Secondary loss of VA was associated with the presence of pigment epithelial detachment (PED) at baseline (p 0.01), but not with baseline fibrosis/atrophy/hemorrhage, CRT fluctuations, or initial VA response. Chart analysis revealed additional individual explanations for the secondary loss of VA, including retinal pigment epithelial tears, progressive fibrosis, and atrophy.

Conclusions

Tissue damage due to degeneration of PED, retinal pigment epithelial tears, progressive fibrosis, progressive atrophy, or massive hemorrhage, appears to be relevant in causing secondary loss of VA despite vascular endothelial growth factor suppression. PED at baseline may represent a risk factor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444

    Article  PubMed  CAS  Google Scholar 

  2. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57–65

    Article  PubMed  Google Scholar 

  3. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431

    Article  PubMed  CAS  Google Scholar 

  4. Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150:315–324

    Article  PubMed  CAS  Google Scholar 

  5. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239–248

    Article  PubMed  CAS  Google Scholar 

  6. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prunte C, Schmidt-Erfurth U, Tano Y, Wolf S (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94:2–13

    Article  PubMed  CAS  Google Scholar 

  7. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A (2011) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration The EXCITE Study. Ophthalmology 118:831–839

    Article  PubMed  Google Scholar 

  8. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583

    Article  PubMed  CAS  Google Scholar 

  9. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR (2007) Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:246–252

    Article  PubMed  Google Scholar 

  10. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144:850–857

    Article  PubMed  CAS  Google Scholar 

  11. Menghini M, Kurz-Levin MM, Amstutz C, Michels S, Windisch R, Barthelmes D, Sutter FK (2010) Response to ranibizumab therapy in neovascular. Klin Monbl Augenheilkd 227:244–248

    Article  PubMed  CAS  Google Scholar 

  12. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B (2011) Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 118:523–530

    Article  PubMed  Google Scholar 

  13. Tao Y, Jonas JB (2010) Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes. Retina 30:1426–1431

    Article  PubMed  Google Scholar 

  14. Chan CK, Meyer CH, Gross JG, Abraham P, Nuthi AS, Kokame GT, Lin SG, Rauser ME, Kaiser PK (2007) Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 27:541–551

    Article  PubMed  Google Scholar 

  15. Chan CK, Abraham P, Meyer CH, Kokame GT, Kaiser PK, Rauser ME, Gross JG, Nuthi AS, Lin SG, Daher NS (2010) Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina 30:203–211

    Article  PubMed  Google Scholar 

  16. Kook D, Wolf A, Neubauer AS, Haritoglou C, Priglinger SG, Kampik A, Ulbig MW (2008) Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress. Ophthalmologe 105:158–164

    Article  PubMed  CAS  Google Scholar 

  17. Weinberger AW, Thiel M, Mohammadi B, Theofylaktopoulos I, Thumann G, Walter P (2007) Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol 144:294–296

    Article  PubMed  CAS  Google Scholar 

  18. Arias L, Caminal JM, Rubio M, Pujol O, Arruga J (2007) Retinal pigment epithelial tears after intravitreal bevacizumab injection for predominantly classic choroidal neovascularization. Eur J Ophthalmol 17:992–995

    PubMed  CAS  Google Scholar 

  19. Konstantinidis L, Ambresin A, Zografos L, Mantel I (2010) Retinal pigment epithelium tears after intravitreal injection of ranibizumab for predominantly classic neovascular membranes secondary to age-related macular degeneration. Acta Ophthalmol 88:736–741

    Article  PubMed  Google Scholar 

  20. Gerding H, Loukopoulos V, Riese J, Herner L, Timmermann M (2011) Results of flexible ranibizumab treatment in age-related macular degeneration and search of parameters with impact on outcome. Graefes Arch Clin Exp Ophthalmol 249:653–662

    Article  PubMed  CAS  Google Scholar 

  21. Heimes B, Lommatzsch A, Zeimer M, Gutfleisch M, Spital G, Dietzel M, Pauleikhoff D (2011) Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol 249:639–644

    Article  PubMed  CAS  Google Scholar 

  22. Rothenbuehler SP, Waeber D, Brinkmann CK, Worl S, Wolf-Schnurrbusch UEK (2009) Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 147:831–837

    Article  PubMed  CAS  Google Scholar 

  23. Querques G, Azrya S, Martinelli D, Berboucha E, Feldman A, Pece A, Coscas G, Soubrane G, Souied E (2010) Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol 94:292–296

    Article  PubMed  Google Scholar 

  24. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG (2009) A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116:1731–1739

    Article  PubMed  Google Scholar 

  25. Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Ahaye-Mazza C, Guiberteau B, Quentel G (2009) Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 148:409–413

    Article  PubMed  CAS  Google Scholar 

  26. Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK (2009) Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 116:1740–1747

    Article  PubMed  Google Scholar 

  27. Mantel I, Zografos L, Ambresin A (2008) Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration. Ophthalmologica 222:321–323

    Article  PubMed  CAS  Google Scholar 

  28. Giani A, Cigada M, Esmaili DD, Salvetti P, Luccarelli S, Marziani E, Luiselli C, Sabella P, Cereda M, Eandi C, Staurenghi G (2010) Artifacts in automatic retinal segmentation using different optical coherence tomography instruments. Retina 30:607–616

    Article  PubMed  Google Scholar 

  29. Gerding H (2010) Behandlung der feuchten altersabhangigen Makuladegeneration mit weniger als 12 Ranibizumab-Injektionen pro Jahr. Klin Monbl Augenheilkd 227:294–297

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

None.

Financial disclosure

None.

Author information

Authors and Affiliations

  1. Ophthalmology Department, University of Lausanne, Jules-Gonin Eye Hospital, 15 Av. de France, Case Postale 133, 1000, Lausanne 7, Switzerland

    Alessandro Mariani, Angeliki Deli, Aude Ambresin & Irmela Mantel

Authors
  1. Alessandro Mariani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angeliki Deli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aude Ambresin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Irmela Mantel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irmela Mantel.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 26 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mariani, A., Deli, A., Ambresin, A. et al. Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 249, 1635–1642 (2011). https://doi.org/10.1007/s00417-011-1734-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-011-1734-5

Keywords

Search

Navigation